Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
Innovus Pharmaceuticals, Inc. (Innovus Pharma), an emerging commercial stage pharmaceutical company, has initiated a pre-clinical and clinical programme intended to evaluate the safety and efficacy of the combination of its supplement Vesele for promoting sexual health with sildenafil indicated for treating erectile dysfunction. Sildenafil in the US is sold under the name Viagra by Pfizer, Inc. (Pfizer).
Amgen announced that new data on Imlygic (talimogene laherparepvec) in combination with an immune checkpoint inhibitor and results from retrospective analyses on Vectibix (panitumumab) will be presented at the European Society for Medical Oncology (ESMO) 2016 Congress, October 7-11, 2016, in Copenhagen.
Eisai Co., Ltd. announced that its U.S. subsidiary Eisai Inc. has launched BELVIQ XR® 20mg tablets, a new once-daily formulation of BELVIQ® (generic name: lorcaserin hydrochloride) for chronic weight management in the United States.
BELVIQ XR is an extended release formulation proven to be slowly absorbed in the body and to last throughout the day. The availability of once-daily BELVIQ XR (20mg) in a single tablet provides patients with another dosing option in addition to the conventional twice-daily BELVIQ (10mg).
Elanco US, Inc., a subsidiary of Eli Lilly and Company, announced an agreement to acquire Boehringer Ingelheim Vetmedica, Inc.'s (BIVI) US feline, canine and rabies vaccines portfolio – as well as a fully integrated manufacturing and R&D site – for $885 million, including the estimated cost of acquired inventory. The deal will diversify Elanco's US companion animal portfolio by complementing its offerings for dogs and cats.
[adsense:336x280:8701650588]
Elixirgen, LLC, a Baltimore-based biotechnology company, launched Quick-Muscle 1.0, a groundbreaking biological reagent that develops skeletal muscle cells from human stem cells in just a few days — a cutting-edge advancement for a laboratory process that previously took a month or longer.
Eisai Co., Ltd. and KYORIN Holdings, Inc. announced that Eisai's Thai subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched Uritos® Tablets (generic name: imidafenacin), a therapeutic agent for overactive bladder, in Thailand.
Janssen Research & Development, LLC (Janssen) announced findings from the first of three pivotal Phase 3 studies evaluating guselkumab, a subcutaneously administered anti-interleukin (IL)-23 monoclonal antibody in late-stage development for the treatment of adults with moderate to severe plaque psoriasis.
Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the European Commission (EC) has approved the transfer of the marketing authorisation for Alprolix® (eftrenonacog alfa), a recombinant clotting factor therapy developed for the treatment of haemophilia B, from Biogen[i] to Sobi, making Sobi the marketing authorisation holder (MAH) in the EU.
AstraZeneca has entered into an agreement with Aralez Pharmaceuticals Trading DAC, a subsidiary of Aralez Pharmaceuticals Inc., for the rights to branded and authorised generic Toprol-XL (metoprolol succinate) in the US. Toprol-XL is a beta-blocker medicine for the control of hypertension (high blood pressure), angina (chest pain) and heart failure. It was first approved in the US in 1992.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
